Irbesartan inhibits advanced glycation end product-induced increase in asymmetric dimethylarginine level in mesangial cells through its anti-oxidative properties

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 1120-1122

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Ueda, Seiji ^a   Fukami, Kei ^a   Okuda, Seiya ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADMA; AGEs; DDAH; Irbesartan; Oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; ARGININE; BIPHENYL DERIVATIVE; IRBESARTAN; N,N-DIMETHYLARGININE; TETRAZOLE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECTS; HUMAN; MESANGIUM CELL; METABOLISM;

ANTIOXIDANTS; ARGININE; BIPHENYL COMPOUNDS; CELLS, CULTURED; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MESANGIAL CELLS; TETRAZOLES;

EID: 84908158695     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.299     Document Type: Article

References (15)

1. P. Cravedi, P. Ruggenenti, and G. Remuzzi Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep 9 2005 430 436
2. S. Yamagishi, K. Nakamura, and T. Matsui Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders Curr Mol Med 7 2007 463 469
3. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
4. P.H. Groop, C. Forsblom, and M.C. Thomas Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes Nat Clin Pract Endocrinol Metab 1 2005 100 110
5. C. Rask-Madsen, and G.L. King Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes Nat Clin Pract Endocrinol Metab 3 2007 46 56
6. S. Yamagishi, and T. Matsui Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharmacol Res 64 2011 187 194
7. S. Theilade, M. Lajer, A. Jorsal, L. Tarnow, H.H. Parving, and P. Rossing Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes Diabet Med 29 2012 990 994
8. R. Ando, S. Ueda, and S. Yamagishi Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction Diabetes Vasc Dis Res 10 2013 436 441
9. S. Ueda, S. Yamagishi, M. Yokoro, and S. Okuda Role of asymmetric dimethylarginine in cardiorenal syndrome Curr Pharm Des 20 2014 2448 2455
10. Y. Ishibashi, T. Matsui, S. Ueda, K. Fukami, and S. Yamagishi Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression Cardiovasc Diabetol 13 2014 60
11. K. Fukami, S. Ueda, and S. Yamagishi AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction Kidney Int 66 2004 2137 2147
12. Y. Ishibashi, T. Matsui, and S. Yamagishi Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression in mesangial cells by restoring angiotensin-converting enzyme 2 level Horm Metab Res 46 2014 379 383
13. Y. Ishibashi, S. Yamagishi, and T. Matsui Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level Metabolism 61 2012 1067 1072
14. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression Pharmacol Res 61 2010 34 39
15. M.R. Marino, K. Langenbacher, N.F. Ford, and H.D. Uderman Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects J Clin Pharmacol 138 1998 246 255